Capitol Street’s health policy experts regularly contribute to leading national and healthcare media, as well as industry conferences and events.

Please contact us at the link below if you have a media request. Any time-sensitive inquiries will be addressed within the hour.

View a selection of recent media and panel appearances below.

View Clip

On August 29th, Smolinski shared with Squawk on the Street Capitol Street’s take on the Top Ten list of Medicare negotiated drugs for 2026 – winners, losers, and surprises.

Read Article (With Subscription)

May 24, 2023

Smolinski was interviewed about the CMS proposal for a Medicaid drug price name and shame policy. CMS has proposed a new Medicaid rule aimed at increasing transparency around some drug prices and PBM practices. Under the proposal, Medicaid would not be given power over drug prices. Rather, it would create what Capitol Street consultants call a “Medicaid Rx wall of shame” on which it would post the prices of three to 10 drugs Medicaid believes have abnormally high prices or have been subject to large price increases. 

JP Morgan keynote discussion with FDA Commissioner Califf and ARPA-H Director Wegrzyn

Replay Segment

January 10, 2023

For the Jan. 10 lunchtime keynote at the JP Morgan Healthcare Conference, Ipsita Smolinski of Capitol Street and Rachel Vatnsdal of JP Morgan co-host a discussion with FDA Commissioner Robert Califf and ARPA-H Director Renee Wegrzyn about the Biden Administration’s 2023 priorities for Life Sciences, BioPharma and MedTech.

Implications of the Midterm Elections for Health Care Policy

View Webinar

November 30, 2022

Smolinski discussed upcoming priorities for the lame-duck session of the 117th Congress, implications for the 118th Congress, and priorities for the Biden Administration.

Smolinski hosts panel at annual AVBCC conference on October 19, 2022

Senate Democrats pass sweeping healthcare, tax and climate bill

Read Article

August 7, 2022

Smolinski provides biopharmaceutical business impact of CPI (inflationary) Rebate policy in the Inflation Reduction Act of 2022.

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

Read Article

August 7, 2022

Smolinski provides market perspective on the Medicare drug negotiation provision of the Inflation Reduction Act.

U.S. Elections May Thwart Democratic Effort to Cap Insulin Cost

Read Article

May 6, 2022

Smolinski interviewed about prospects for lawmakers’ attempts to cut the cost of insulin to $35 per month.

Big Pharma Quietly Pushes Back on Global Tax Deal, Citing Covid-19 Role

Read Article

July 27, 2021

Smolinski interviewed for WSJ article about U.S. tax policy and its effect on pharmaceutical companies in light of European countries’ push to harmonize minimum corporate tax rates.

Planning for Fiscal Strength in Changing Times

Read Overview

During a June 23 virtual event presented by Allscripts and Modern Healthcare Custom Media, Ipsita Smolinski, Managing Partner of Capitol Street Research and Senior Strategic Adviser at McAllister & Quinn, and Richard Mulry, President and CEO of Northwell Holdings and Ventures, offered insights into and guidance specific to where hospital systems should be prioritizing as they do strategic planning, during a COVID time of health equity and physician employment along with increasing transparency rules for health systems, looking ahead to the next several years.

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

View Article

July 8, 2021

Smolinski was interviewed for a STAT News article about the FDA’s June 2021 approval of Aduhelm as a treatment for Alzheimer’s disease using the accelerated approval pathway.